|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: FNDC3A |
Gene summary for FNDC3A |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | FNDC3A | Gene ID | 22862 |
| Gene name | fibronectin type III domain containing 3A | |
| Gene Alias | FNDC3 | |
| Cytomap | 13q14.2 | |
| Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | A0A024RDT9 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 22862 | FNDC3A | HTA11_3410_2000001011 | Human | Colorectum | AD | 3.01e-13 | -5.09e-01 | 0.0155 |
| 22862 | FNDC3A | HTA11_2487_2000001011 | Human | Colorectum | SER | 1.95e-04 | -4.79e-01 | -0.1808 |
| 22862 | FNDC3A | HTA11_3361_2000001011 | Human | Colorectum | AD | 1.12e-06 | -4.74e-01 | -0.1207 |
| 22862 | FNDC3A | HTA11_866_2000001011 | Human | Colorectum | AD | 8.41e-03 | -3.13e-01 | -0.1001 |
| 22862 | FNDC3A | HTA11_5212_2000001011 | Human | Colorectum | AD | 4.19e-04 | -7.19e-01 | -0.2061 |
| 22862 | FNDC3A | HTA11_7862_2000001011 | Human | Colorectum | AD | 4.94e-02 | -4.91e-01 | -0.0179 |
| 22862 | FNDC3A | HTA11_866_3004761011 | Human | Colorectum | AD | 6.27e-04 | -4.25e-01 | 0.096 |
| 22862 | FNDC3A | HTA11_8622_2000001021 | Human | Colorectum | SER | 1.90e-04 | -6.04e-01 | 0.0528 |
| 22862 | FNDC3A | HTA11_10711_2000001011 | Human | Colorectum | AD | 4.76e-08 | -5.32e-01 | 0.0338 |
| 22862 | FNDC3A | HTA11_7696_3000711011 | Human | Colorectum | AD | 9.14e-08 | -4.49e-01 | 0.0674 |
| 22862 | FNDC3A | HTA11_6818_2000001021 | Human | Colorectum | AD | 4.86e-03 | -4.32e-01 | 0.0588 |
| 22862 | FNDC3A | HTA11_99999965104_69814 | Human | Colorectum | MSS | 1.67e-02 | 4.97e-01 | 0.281 |
| 22862 | FNDC3A | HTA11_99999974143_84620 | Human | Colorectum | MSS | 4.38e-11 | -4.89e-01 | 0.3005 |
| 22862 | FNDC3A | A001-C-207 | Human | Colorectum | FAP | 6.14e-05 | -2.24e-01 | 0.1278 |
| 22862 | FNDC3A | A015-C-203 | Human | Colorectum | FAP | 1.45e-30 | -4.47e-01 | -0.1294 |
| 22862 | FNDC3A | A015-C-204 | Human | Colorectum | FAP | 1.37e-06 | -2.82e-01 | -0.0228 |
| 22862 | FNDC3A | A014-C-040 | Human | Colorectum | FAP | 1.67e-04 | -2.55e-01 | -0.1184 |
| 22862 | FNDC3A | A002-C-201 | Human | Colorectum | FAP | 3.51e-15 | -4.41e-01 | 0.0324 |
| 22862 | FNDC3A | A002-C-203 | Human | Colorectum | FAP | 9.30e-04 | -1.44e-01 | 0.2786 |
| 22862 | FNDC3A | A001-C-119 | Human | Colorectum | FAP | 8.49e-11 | -5.36e-01 | -0.1557 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0002064 | Colorectum | AD | epithelial cell development | 89/3918 | 220/18723 | 2.98e-11 | 3.52e-09 | 89 |
| GO:0061458 | Colorectum | AD | reproductive system development | 116/3918 | 427/18723 | 1.11e-03 | 1.01e-02 | 116 |
| GO:0048608 | Colorectum | AD | reproductive structure development | 114/3918 | 424/18723 | 1.78e-03 | 1.47e-02 | 114 |
| GO:0060009 | Colorectum | AD | Sertoli cell development | 7/3918 | 12/18723 | 5.09e-03 | 3.38e-02 | 7 |
| GO:00020641 | Colorectum | SER | epithelial cell development | 64/2897 | 220/18723 | 1.96e-07 | 1.10e-05 | 64 |
| GO:00614581 | Colorectum | SER | reproductive system development | 87/2897 | 427/18723 | 3.69e-03 | 3.07e-02 | 87 |
| GO:00600091 | Colorectum | SER | Sertoli cell development | 6/2897 | 12/18723 | 5.42e-03 | 4.03e-02 | 6 |
| GO:00486081 | Colorectum | SER | reproductive structure development | 85/2897 | 424/18723 | 6.33e-03 | 4.56e-02 | 85 |
| GO:00020642 | Colorectum | MSS | epithelial cell development | 81/3467 | 220/18723 | 1.02e-10 | 1.06e-08 | 81 |
| GO:00614582 | Colorectum | MSS | reproductive system development | 115/3467 | 427/18723 | 9.86e-06 | 2.39e-04 | 115 |
| GO:00486082 | Colorectum | MSS | reproductive structure development | 113/3467 | 424/18723 | 1.94e-05 | 4.18e-04 | 113 |
| GO:00020644 | Colorectum | FAP | epithelial cell development | 62/2622 | 220/18723 | 2.74e-08 | 2.54e-06 | 62 |
| GO:00614583 | Colorectum | FAP | reproductive system development | 85/2622 | 427/18723 | 4.30e-04 | 5.13e-03 | 85 |
| GO:00486083 | Colorectum | FAP | reproductive structure development | 84/2622 | 424/18723 | 5.40e-04 | 6.10e-03 | 84 |
| GO:00020645 | Colorectum | CRC | epithelial cell development | 55/2078 | 220/18723 | 4.63e-09 | 1.16e-06 | 55 |
| GO:00614584 | Colorectum | CRC | reproductive system development | 73/2078 | 427/18723 | 1.13e-04 | 2.22e-03 | 73 |
| GO:00486084 | Colorectum | CRC | reproductive structure development | 72/2078 | 424/18723 | 1.55e-04 | 2.80e-03 | 72 |
| GO:00614589 | Endometrium | AEH | reproductive system development | 88/2100 | 427/18723 | 9.50e-09 | 6.41e-07 | 88 |
| GO:00486089 | Endometrium | AEH | reproductive structure development | 87/2100 | 424/18723 | 1.43e-08 | 9.12e-07 | 87 |
| GO:000206415 | Endometrium | AEH | epithelial cell development | 43/2100 | 220/18723 | 1.94e-04 | 2.48e-03 | 43 |
| Page: 1 2 3 4 5 6 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| FNDC3A | SNV | Missense_Mutation | novel | c.3337N>A | p.Glu1113Lys | p.E1113K | Q9Y2H6 | protein_coding | deleterious(0.03) | benign(0.155) | TCGA-3C-AALI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Poly E | Complete Response |
| FNDC3A | SNV | Missense_Mutation | novel | c.1842N>A | p.Met614Ile | p.M614I | Q9Y2H6 | protein_coding | tolerated(0.49) | benign(0.003) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
| FNDC3A | SNV | Missense_Mutation | c.2014G>T | p.Gly672Cys | p.G672C | Q9Y2H6 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| FNDC3A | SNV | Missense_Mutation | novel | c.568N>G | p.Leu190Val | p.L190V | Q9Y2H6 | protein_coding | tolerated(0.07) | benign(0.297) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| FNDC3A | SNV | Missense_Mutation | novel | c.1842N>A | p.Met614Ile | p.M614I | Q9Y2H6 | protein_coding | tolerated(0.49) | benign(0.003) | TCGA-AO-A0JC-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | fluorouracil | SD |
| FNDC3A | SNV | Missense_Mutation | c.971T>C | p.Val324Ala | p.V324A | Q9Y2H6 | protein_coding | tolerated(0.21) | benign(0.044) | TCGA-D8-A140-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin+cyclophosphamid | SD | |
| FNDC3A | deletion | In_Frame_Del | c.2623_2625delTCT | p.Ser875del | p.S875del | Q9Y2H6 | protein_coding | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |||
| FNDC3A | SNV | Missense_Mutation | c.2602G>A | p.Glu868Lys | p.E868K | Q9Y2H6 | protein_coding | tolerated(0.69) | benign(0.101) | TCGA-LP-A5U2-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD | |
| FNDC3A | SNV | Missense_Mutation | rs201004322 | c.826N>A | p.Asp276Asn | p.D276N | Q9Y2H6 | protein_coding | tolerated(0.71) | benign(0.005) | TCGA-Q1-A5R2-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PR |
| FNDC3A | SNV | Missense_Mutation | rs771506910 | c.2206N>T | p.Arg736Cys | p.R736C | Q9Y2H6 | protein_coding | deleterious(0) | benign(0.188) | TCGA-5M-AAT6-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
| Page: 1 2 3 4 5 6 7 8 9 10 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |